Table 2.

Prevalence of TDR classified by drug classes and years and comparison of the odds of having at least one resistance mutation between years

	NRTI	NNRTI	PI	Any
Prevalence, % (95% CI)
2008	0.8 (0–4.4)	0.8 (0–4.4)	3.2 (0.9–8.1)	4.0 (1.5–9.6)
2009	2.4 (0.3–8.3)	3.6 (0.7–10.1)	1.2 (0–6.5)	5.9 (2.2–14.0)
2010	5.3 (1.5–12.9)	5.3 (1.4–12.9)	1.3 (0.3–7.1)	5.3 (1.7–13.6)
Comparison, OR (95% CI)
2009 versus 2008	3.0 (0.2–178.2) P = 0.57	4.5 (0.4–240.7) P = 0.31	0.4 (0–3.8) P = 0.65	1.5 (0.33–6.8) P = 0.53
2010 versus 2008	6.8 (0.7–338.6) P = 0.07	6.8 (0.7–338.6) P = 0.07	0.4 (0.1–4.2) P = 0.65	1.3 (0.25–1.3) P = 0.73
2010 versus 2009	2.3 (0.3–25.8) P = 0.42	1.5 (0.2–10.6) P = 0.71	1.1 (0.01–87.8) P = 1.0	0.88 (0.17–4.3) P = 1.0